The TheraMe! Consortium has a comprehensive patent portfolio

The core technology of the TheraMe! approach is covered by a granted US patent (US20140332083A1). Furthermore, we have filed two more patent applications on additional technology that also protect our future developments (EP14186463.7 and EP15174088.3). Taken together, the TheraMe! consortium has a comprehensive patent portfolio, putting it in a unique position to offer microfluidics-guided personalized medicine approaches.

Green light for commercial exploitation of the TheraMe! approach

The FTO analysis carried out by a professional patent law firm showed that the commercial use of droplet microfluidic systems as used in the TheraMe! platform is likely not to be dependent on other patents than our own proprietary technology.